FDA turns down Hetlioz for jet lag once again
Vanda Pharma may have forced the FDA to revisit its marketing application for Hetlioz as a therapy for…
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
WASHINGTON, Jan. 8, 2026 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has received…